1. Home
  2. FBIO vs ADVM Comparison

FBIO vs ADVM Comparison

Compare FBIO & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FBIO
  • ADVM
  • Stock Information
  • Founded
  • FBIO 2006
  • ADVM 2006
  • Country
  • FBIO United States
  • ADVM United States
  • Employees
  • FBIO N/A
  • ADVM N/A
  • Industry
  • FBIO Biotechnology: Pharmaceutical Preparations
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FBIO Health Care
  • ADVM Health Care
  • Exchange
  • FBIO Nasdaq
  • ADVM Nasdaq
  • Market Cap
  • FBIO 49.1M
  • ADVM 47.4M
  • IPO Year
  • FBIO N/A
  • ADVM 2014
  • Fundamental
  • Price
  • FBIO $1.88
  • ADVM $2.39
  • Analyst Decision
  • FBIO Strong Buy
  • ADVM Strong Buy
  • Analyst Count
  • FBIO 2
  • ADVM 5
  • Target Price
  • FBIO $21.00
  • ADVM $23.80
  • AVG Volume (30 Days)
  • FBIO 233.4K
  • ADVM 338.5K
  • Earning Date
  • FBIO 08-12-2025
  • ADVM 08-11-2025
  • Dividend Yield
  • FBIO N/A
  • ADVM N/A
  • EPS Growth
  • FBIO N/A
  • ADVM N/A
  • EPS
  • FBIO N/A
  • ADVM N/A
  • Revenue
  • FBIO $57,784,000.00
  • ADVM $1,000,000.00
  • Revenue This Year
  • FBIO $51.59
  • ADVM N/A
  • Revenue Next Year
  • FBIO $44.74
  • ADVM $18.82
  • P/E Ratio
  • FBIO N/A
  • ADVM N/A
  • Revenue Growth
  • FBIO N/A
  • ADVM N/A
  • 52 Week Low
  • FBIO $1.33
  • ADVM $1.78
  • 52 Week High
  • FBIO $2.89
  • ADVM $10.14
  • Technical
  • Relative Strength Index (RSI)
  • FBIO 53.63
  • ADVM 44.19
  • Support Level
  • FBIO $1.76
  • ADVM $2.11
  • Resistance Level
  • FBIO $1.89
  • ADVM $2.60
  • Average True Range (ATR)
  • FBIO 0.10
  • ADVM 0.22
  • MACD
  • FBIO -0.01
  • ADVM -0.00
  • Stochastic Oscillator
  • FBIO 75.00
  • ADVM 33.33

About FBIO Fortress Biotech Inc.

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

Share on Social Networks: